Martin has over 20 years of experience in all fields of intellectual property, including litigation, patent and trademark prosecution and counseling. He has prepared and prosecuted hundreds of patent applications in the United States, and has coordinated and supervised prosecution of various patent portfolios around the world. He has extensive experience in Hatch-Waxman matters including counseling generic pharmaceutical clients on various patent issues and filing strategies.
Martin has also served as counsel in numerous Hatch-Waxman patent infringement actions including:
- Abbott Laboratories v. Andrx Pharmaceuticals, Inc., relating to BIAXIN® XL
- Hoechst Marion Roussel, Inc. v. Andrx Corp., relating to CARDIZEM® CD
- Schering Corp. v. Geneva Pharmaceuticals, Inc., relating to CLARITIN-D® 24 and CLARITIN-D® 12
- Biovail Labs. Intern. SRL v. Andrx Pharm. LLC, relating to CARDIZEM® LA
- Biovail Corp. Intern. v. Andrx Pharmaceuticals, Inc., relating to TIAZAC®
- Abbott Laboratories v. Andrx Corp., relating to DEPAKOTE®
- Smithkline Beecham v. Andrx Pharmaceuticals, Inc., relating to PAXIL®
- Astra Aktiebolag v. Andrx Pharmaceuticals, Inc., relating to PRILOSEC®